LetterLetter
Upfront Combination Therapy With Rituximab and Mycophenolate Mofetil for Progressive Systemic Sclerosis
Doron Rimar, Itzhak Rosner and Gleb Slobodin
The Journal of Rheumatology October 2020, jrheum.200484; DOI: https://doi.org/10.3899/jrheum.200484
Doron Rimar
Rheumatology Unit, Bnai-Zion Medical Center, Faculty of Medicine, Technion, Haifa, Israel. Address correspondence to Dr. D. Rimar, Rheumatology Unit, Bnai Zion Medical Center, POB 4940, Haifa, 31048 Israel. Email: doronrimar@gmail.com. This study has been approved by the Bnai-Zion ethics committee (ethics board approval number BZ-20-0073). Informed consent was obtained from all recruited patients.
Itzhak Rosner
Rheumatology Unit, Bnai-Zion Medical Center, Faculty of Medicine, Technion, Haifa, Israel. Address correspondence to Dr. D. Rimar, Rheumatology Unit, Bnai Zion Medical Center, POB 4940, Haifa, 31048 Israel. Email: doronrimar@gmail.com. This study has been approved by the Bnai-Zion ethics committee (ethics board approval number BZ-20-0073). Informed consent was obtained from all recruited patients.
Gleb Slobodin
Rheumatology Unit, Bnai-Zion Medical Center, Faculty of Medicine, Technion, Haifa, Israel. Address correspondence to Dr. D. Rimar, Rheumatology Unit, Bnai Zion Medical Center, POB 4940, Haifa, 31048 Israel. Email: doronrimar@gmail.com. This study has been approved by the Bnai-Zion ethics committee (ethics board approval number BZ-20-0073). Informed consent was obtained from all recruited patients.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Upfront Combination Therapy With Rituximab and Mycophenolate Mofetil for Progressive Systemic Sclerosis
Doron Rimar, Itzhak Rosner, Gleb Slobodin
The Journal of Rheumatology Oct 2020, jrheum.200484; DOI: 10.3899/jrheum.200484